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Abstract. 
 
Vesicular transport proteins package classical 
neurotransmitters for regulated exocytotic release, and 
localize to at least two distinct types of secretory vesi-
cles. In PC12 cells, the vesicular acetylcholine trans-
porter (VAChT) localizes preferentially to synaptic-like 
microvesicles (SLMVs), whereas the closely related ve-
sicular monoamine transporters (VMATs) localize 
preferentially to large dense core vesicles (LDCVs). 
VAChT and the VMATs contain COOH-terminal, cy-
toplasmic dileucine motifs required for internalization 
from the plasma membrane. We now show that VAChT 
undergoes regulated phosphorylation by protein kinase 
C on a serine (Ser-480) ﬁve residues upstream of the 
dileucine motif. Replacement of Ser-480 by glutamate, 
to mimic the phosphorylation event, increases the local-
ization of VAChT to LDCVs. Conversely, the VMATs 
contain two glutamates upstream of their dileucine-like 
motif, and replacement of these residues by alanine 
conversely reduces sorting to LDCVs. The results pro-
vide some of the ﬁrst information about sequences in-
volved in sorting to LDCVs. Since the location of the 
transporters determines which vesicles store classical 
neurotransmitters, a change in VAChT trafﬁcking due 
to phosphorylation may also inﬂuence the mode of 
transmitter release.
Key words: neurotransmitter • kinase • trafﬁcking • 
exocytosis • monoamine
 
Introduction
 
At least two distinct populations of secretory vesicles me-
diate the regulated exocytotic release of neurotransmit-
ters. Synaptic vesicles (SVs)
 
1
 
 appear almost exclusively in
nerve terminals where they cluster at the synaptic cleft
(Calakos and Scheller, 1996). In contrast, large dense core
vesicles (LDCVs) appear throughout the cell, and release
transmitter more slowly and in response to different stim-
uli than SVs (De Camilli and Jahn, 1990; Martin, 1994).
Although SVs are generally considered to contain classical
transmitters, whereas LDCVs store neural peptides, both
types of regulated secretory vesicles contain monoamines,
indicating the potential for release of a single transmitter
through two distinct mechanisms (Thureson-Klein, 1983;
Bruns and Jahn, 1995). Since classical transmitters, includ-
ing monoamines, are synthesized in the cytoplasm, the
subcellular location of the transporters required for pack-
aging them into secretory vesicles determines the site of
vesicular storage, and hence, the mode of exocytotic re-
lease.
 
Secretory vesicles exhibit
 
 
 
four distinct neurotransmitter
transport activities, including one for monoamines, a sec-
ond for acetylcholine (ACh), a third for 
 
g
 
-aminobutyric
acid (GABA), and a fourth for glutamate (Liu and Ed-
 
wards, 1997b). All of these activities depend on the H
 
1
 
electrochemical gradient across the vesicle membrane, and
exchange lumenal protons for cytoplasmic transmitter
(Schuldiner et al., 1995). Pharmacologic manipulation of
vesicular transport indicates the importance of these activ-
ities for behavior. The antihypertensive drug reserpine in-
hibits vesicular monoamine transport and induces a syn-
drome resembling depression (Frize, 1954). In addition,
amphetamines induce efflux from vesicular monoamine
stores (Sulzer et al., 1995) and can cause psychosis. Thus,
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changes in vesicular transport activity have the potential
to influence behavior, but the extent to which they un-
dergo regulation has remained unknown.
Molecular cloning has begun to identify the proteins re-
sponsible for neurotransmitter transport into secretory
vesicles. One family of proteins includes two vesicular
monoamine transporters (VMATs) and the vesicular ace-
tylcholine transporter (VAChT). VMAT1 is expressed
principally in peripheral, nonneural tissues and VMAT2 is
expressed by central monoamine neurons (Varoqui and
Erickson, 1997; Liu and Edwards, 1997b). Consistent with
the observed release of monoamines from both SVs and
LDCVs, the VMATs occur on multiple populations of
secretory vesicles. In brain, VMAT2 localizes preferen-
tially to LDCVs, but also resides on SVs, as well as tubu-
lovesicular structures in the cell body and dendrites of cen-
tral dopamine neurons (Nirenberg et al., 1995, 1996).
Similarly, VMAT2 resides predominantly on LDCVs
rather than the synaptic-like microvesicles (SLMVs) pres-
ent in PC12 cells (Liu et al., 1994; Erickson et al., 1996). In
contrast, VAChT localizes predominantly to SVs in brain
(Gilmor et al., 1996; Weihe et al., 1996) and to lighter mem-
branes, including the SLMVs in PC12 cells (Liu and Ed-
wards, 1997a; Varoqui and Erickson, 1998). However,
VAChT also occurs at lower levels on LDCVs in PC12
cells
 
 
 
(Liu and Edwards, 1997a) and in neurons (Lundberg
et al., 1981; Agoston and Whittaker, 1989). Thus, two
closely related vesicular neurotransmitter transporters lo-
calize to distinct populations of secretory vesicles that dif-
fer in their mode of release.
To understand how VMAT2 and VAChT localize to dif-
ferent secretory vesicles, we have sought to identify their
sorting signals. As integral membrane proteins, the trans-
porters presumably depend on signals in their cytoplasmic
domains that interact with a cytosolic sorting machinery.
We have found previously that dileucine motifs located
COOH-terminal to transmembrane domain (TMD) 12 of
both VMAT2 and VAChT (see Fig. 1 A) mediate inter-
nalization of the transporters from the plasma membrane
(Tan et al., 1998). Dileucine motifs implicated in the en-
docytosis of certain other proteins require the presence of
acidic residues at positions 
 
2
 
4 and 
 
2
 
5 relative to the two
leucines (Pond et al., 1995; Dietrich et al., 1997) and the
VMATs contain highly conserved glutamates at both of
these positions. However, replacement of these gluta-
mates with alanine does not impair the internalization of
VMAT2 (Tan et al., 1998). Since dileucine motifs mediate
trafficking at multiple sites in the secretory pathway, these
residues may influence other events, distinct from endo-
cytosis. Although VAChT, like the VMATs, contains a
glutamate at 
 
2
 
4 relative to the dileucine, it contains a serine
at 
 
2
 
5, raising the possibility that the charge of this residue
accounts for the localization of the transporters to distinct
populations of secretory vesicles. In addition, the presence
of a serine at 
 
2
 
5 relative to the dileucine in VAChT sug-
gests that phosphorylation of this residue may influence
the sorting of the transporter. Indeed, phosphorylation of
serine residues at 
 
2
 
5 relative to the dileucine motifs in CD4
(Shin et al., 1991) and CD3
 
g
 
 (Dietrich et al., 1994) dramati-
cally influences the trafficking of these proteins.
We now report that the serine at 
 
2
 
5 relative to the di-
leucine motif in VAChT (Ser-480) undergoes phosphory-
 
lation by a calcium-dependent isoform of protein kinase C
(PKC). Replacement of Ser-480 by alanine, which pre-
vents phosphorylation, reduces the expression of VAChT
on LDCVs relative to the wild-type protein. In contrast,
substitution of Ser-480 by glutamate, to mimic the se-
quence of VMAT2 at this position and the phosphor-
ylation event, increases the expression of VAChT on
LDCVs. Consistent with the importance of acidic residues
upstream of a dileucine motif in sorting to LDCVs, re-
placement of Glu-478 and -479 upstream of the dileucine-
like motif in VMAT2 reduces localization to LDCVs. The
results provide some of the first information about signals
involved in sorting to different classes of secretory vesi-
cles. In addition, they suggest that phosphorylation regu-
lates the targeting of VAChT to LDCVs, providing a po-
tential mechanism to regulate transmitter release.
 
Materials and Methods
 
Cell Culture 
 
All cultures were grown in media containing penicillin and streptomycin
at 37
 
8
 
C in 5% CO
 
2
 
. Monkey kidney COS cells were maintained in DME
containing 10% calf serum. PC12 cells were maintained in DME contain-
ing 5% calf serum and 10% equine serum (Greene and Tischler, 1976).
For transient transfection, COS cells were electroporated with 15–20 
 
m
 
g
DNA using a BioRad Gene Pulser (Peter et al., 1994). Stable PC12 cell
transfectants expressing hemagglutinin (HA)-tagged transporters were
prepared by electroporation of wild-type and mutant VAChT cDNAs in a
modified pCDNA3 expression vector (see below). After selection in
G418,
 
 
 
isolated colonies (
 
z
 
80 per construct) were picked and screened for
expression by immunofluorescence. At least two independently isolated
cell lines were analyzed for each VAChT construct.
 
Mutagenesis and Subcloning 
 
We used the method of Kunkel et al. (1991) to introduce epitope tags and
point mutations into the VAChT cDNA. In brief, we prepared single-
stranded uracil-containing template in the dut
 
2
 
, ung
 
2
 
 
 
CJ236 strain of 
 
E
 
.
 
coli
 
, annealed the mutagenic primer, extended with T7 DNA polymerase,
and transformed the reaction product into XL1-Blue. Oligonucleotides
containing silent restriction enzyme sites to facilitate mapping were syn-
thesized using an Applied Biosystems PCR-Mate. The mutations were
verified by sequence analysis and a small fragment containing the desired
mutation transferred into the wild-type VAChT cDNA in the expression
vector pCDNA3 (Invitrogen) with an RSV promoter replacing the origi-
nal CMV promoter. For expression of bacterial glutathione S-transferase
(GST) fusion proteins (Smith and Johnson, 1988), cDNA fragments of
wild-type and mutant VAChT were cut at VAChT nucleotide 1,473 using
StuI and the multiple cloning site of the parent construct, and the 0.4-kb
fragment inserted in frame into the SmaI site of the pGEX-5X-1 bacterial
expression vector (Pharmacia Biotech).
 
Metabolic Labeling and Immunoprecipitation
 
For metabolic labeling with 
 
32
 
P
 
i
 
, cells were washed three times in media
lacking phosphate, and incubated for 4 h at 37
 
8
 
C in the presence of 0.5–1.0
mCi/ml 
 
32
 
P
 
i 
 
(ICN). For kinase stimulation experiments, pharmacological
agents at the concentrations indicated in the text were added from stock
solutions by rapid mixing during the last 15 min of labeling. After labeling,
the cells were washed in ice-cold PBS and harvested by scraping into 1 ml
50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 0.2 mM Na
 
3
 
VO
 
4
 
, 10
mM EDTA, 5 mM EGTA, 10 
 
m
 
g/ml PMSF, 2 
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml
pepstatin, 1% vol/vol Triton X-100 detergent (homogenization buffer,
HB). After removal of the nuclei and cell debris by centrifugation at
14,000 
 
g
 
 for 5 min at 4
 
8
 
C, SDS was added to the supernatant to a final con-
centration of 0.2%. For immunoprecipitation, the mixture was incubated
overnight at 4
 
8
 
C with either the polyclonal antiserum to VAChT pre-
bound to protein A–Sepharose (Sigma Chemical Co.) or with an mAb to
HA (Berkeley Antibody Co.) prebound to protein G–Sepharose. Immune
complexes were washed 4 times in HB containing 0.2% SDS, resuspended 
Krantz et al. 
 
VAChT Sorting to LDCVs
 
381
 
in 2
 
3
 
 Laemmli sample buffer and the proteins separated by electrophore-
sis through 10% polyacrylamide. The gels were then fixed in 10% acetic
acid, 50% methanol, dried, and submitted to autoradiography.
 
Western Analysis
 
Proteins were separated by electrophoresis through polyacrylamide con-
taining SDS and transferred to nitrocellulose or PVDF using either a
semidry or liquid transfer apparatus. The filters were then incubated in
PBS containing 0.1% Tween 20 and 5% nonfat dry milk, and stained in
the same buffer with either a primary rabbit polyclonal antibody to
VAChT at 1:1,000 (Liu and Edwards, 1997a) or an mAb to HA (Berkeley
Antibody Co.) at 1:1,000, followed by the appropriate secondary antibody
conjugated to HRP (1:1,000). The complex was then visualized by chemi-
luminescence (Pierce Chemical Co.), and the exposed films scanned using
a UMAX flatbed scanner and Adobe Photoshop for Macintosh. The digi-
tized images were quantitated using NIH Image 1.61 software.
 
Phosphoamino Acid Analysis
 
Phosphoamino acid analysis was performed as previously described
(Krantz et al., 1997). In brief, extracts prepared from cells metabolically
labeled with 
 
32
 
P
 
i
 
 were immunoprecipitated with the polyclonal antiserum
to VAChT as described above, and the immunoprecipitates separated by
electrophoresis through polyacrylamide. After autoradiography, the ra-
diolabeled band was excised from the gel, rehydrated in 50 mM ammo-
nium bicarbonate, and the protein was eluted overnight in 0.2% SDS, 2%
 
b
 
-mercaptoethanol. The eluate was precipitated with 20% TCA and par-
tially hydrolyzed by boiling in 5.7 M HCl for 60 min. The hydrolysate was
washed first with distilled water, then with 7.8% acetic acid, 2.2% formic
acid (pH 1.9 buffer), resuspended in 10 
 
m
 
l pH 1.9 buffer containing phos-
phoamino acid standards, and spotted onto thin layer cellulose plates.
Electrophoresis was performed at 4
 
8
 
C using pH 1.9 buffer for the first di-
mension and 5% acetic acid, 0.5% pyridine (pH 3.5 buffer) for the second
dimension. The standards were then stained with ninhydrin and the plates
submitted to autoradiography.
 
In Vitro Phosphorylation
 
To express GST fusion proteins, 
 
Escherichia coli
 
 were grown overnight in
1.6% tryptone, 1% yeast extract, 0.5% NaCl (2
 
3
 
 YTA media) at 37
 
8
 
C,
and induced in 0.1 mM isopropyl 
 
b
 
-
 
D
 
-thiogalactoside (IPTG) for an addi-
tional 3–6 h at room temperature. Bacteria were then pelleted, resus-
pended in PBS, and disrupted by vigorous sonication for 1–2 min at 0
 
8
 
C.
Cell debris was removed by centrifugation at 14,000 
 
g
 
 and the resulting su-
pernatant was either used immediately or stored at 
 
2
 
70
 
8
 
C. To partially
purify the fusion protein, the cleared extract was bound to glutathione-
Sepharose beads for 20 min at room temperature in PBS, washed twice in
PBS, and once in either 20 mM Tris, pH 7.5, 0.5 mM DTT, 10 mM MgCl
 
2
 
(lysate kinase buffer, LKB), or 50 mM MES, pH 6.0, 1.25 mM EGTA, 12.5
mM MgCl
 
2
 
 (PKC buffer, PKCB). Aliquots of fusion protein (
 
z
 
1 
 
m
 
g)
bound to glutathione-sepharose (10–20 
 
m
 
l bed vol) were then incubated
with either 1 
 
m
 
l postnuclear supernatant (PNS; 
 
z
 
10 
 
m
 
g total protein) from
COS or PC12 cells (see below) for 20 min at 30
 
8
 
C in LKB containing 2
mM CaCl
 
2,
 
 unless otherwise indicated, and 200 
 
m
 
M ATP and 
 
g
 
[
 
32
 
P]ATP,
to a final specific activity of 500 
 
m
 
Ci/
 
m
 
mol; or with 20 ng (0.02 units) of the
catalytic fragment of PKC from rat brain (PKC-M; Calbiochem) for 20
min at 30
 
8
 
C in PKCB containing 125 
 
m
 
M ATP and 
 
g
 
[
 
32
 
P]ATP, to a final
specific activity of 5,000 
 
m
 
Ci/
 
m
 
mol. For experiments using kinase inhibi-
tors, the ATP concentration was reduced to 1 
 
m
 
M. The reactions were
stopped by washing with cold PBS containing 15 mM EDTA, the phos-
phorylated proteins were eluted with 20 
 
m
 
l of 10 mM glutathione in 50
mM Tris-HCl, pH 8.0, and the eluates were added to an equal volume of
2
 
3
 
 Laemmli sample buffer before separation by electrophoresis through
12.5% polyacrylamide. The gels were fixed and stained with Coomassie
blue, and then dried and submitted to autoradiography.
Preparation of a PNS was performed as previously described (Krantz et
al., 1997). In brief, cells were harvested using either trypsin or a cell
scraper after one freeze–thaw cycle. The cells were resuspended in 10 mM
Hepes-KOH, pH 7.4, 320 mM sucrose, 10 mM EDTA, 5 mM EGTA, 20
 
m
 
g/ml PMSF, 2 
 
m
 
g/ml leupeptin, 2 
 
m
 
g/ml pepstatin, 1 mM DTT (resuspen-
sion buffer), and disrupted in a bath sonicator (Branson) using 15 pulses
at an intermediate setting. Nuclei and cell debris were removed by sedi-
mentation at 1,300 
 
g
 
 for 5 min at 4
 
8
 
C, and the supernatant stored at 
 
2
 
70
 
8
 
C
before use. To reduce competition with kinase inhibitors, the endogenous
ATP in the added cell extract was reduced tenfold by dilution in resuspen-
 
sion buffer, followed by reconcentration to the original volume by filtra-
tion through a Centricon 10 filtration device (Amicon).
 
Immunofluorescence
 
For immunostaining, PC12 cells were plated onto glass coverslips coated
with poly-
 
D
 
-lysine and Matrigel (Collaborative Research), and treated
with 50 ng/ml NGF for 2–5 d before fixation in 100 mM NaPO
 
4
 
, pH 7.3
containing 4% paraformaldehyde. The cells were then permeabilized in
PBS, pH 7.4, containing 5% bovine serum and 0.1% TX-100 detergent, in-
cubated with primary antibody in the same buffer (1:100–1:1,000), washed
three times for 5 min, and incubated in secondary antibody (1:100) for 1 h.
After washing, the coverslips were mounted onto glass slides using Anti-
fade (Molecular Probes), and visualized by indirect immunofluorescence
with a BioRad 1024 confocal microscope. Digital images were processed
using NIH Image and Adobe Photoshop.
 
Sucrose Gradient Equilibrium Centrifugation
 
To label the dense core granules with [
 
3
 
H]serotonin, PC12 cells were incu-
bated in standard medium containing 5 
 
m
 
Ci [
 
3
 
H]serotonin (Amersham)/15
ml for at least 4 h before cell fractionation. Cell membranes were pre-
pared by homogenization at a clearance of 10 
 
m
 
m in cold Hepes-KOH-
buffered saline (HBS) containing 2 mM Mg EGTA, 1 
 
m
 
g/ml leupeptin, 1
 
m
 
g/ml pepstatin, and 10 
 
m
 
g/ml PMSF. The nuclei and other cell debris
were pelleted by centrifugation at 1,300 
 
g
 
 for 5 min. For sucrose gradient
equilibrium centrifugation, the PNS was layered onto a linear 0.65–1.55 M
(or 0.6–1.6 M, as indicated) sucrose gradient in 10 mM Hepes-KOH and
sedimented to equilibrium at 30,000
 
 
 
rpm for 8–12 h in an SW41 rotor at
4
 
8
 
C. 17 fractions were collected from the bottom of the tube, stored at
 
2
 
70
 
8
 
C, and the radioactivity of fractions from cells preloaded with [
 
3
 
H]
serotonin measured in Ecolume (ICN) using a Beckman 3800 scintillation
counter. For two-step separations, the PNS from cell lysates was first lay-
ered onto a linear 0.3–1.2 M sucrose velocity gradient in 10 mM Hepes
and sedimented at 25,400
 
 
 
rpm for 30 min in an SW41 rotor at 4
 
8
 
C. The ra-
dioactivity in each fraction of the velocity gradient was determined by
scintillation counting, the two peak fractions were pooled, adjusted to a fi-
nal sucrose concentration of 0.6 M, layered onto a linear 0.6–1.6 M sucrose
gradient, and sedimented to equilibrium at 30,000
 
 
 
rpm for 8–12 h in an
SW41 rotor at 4
 
8
 
C, with 12 fractions collected from the bottom of the
tube. Immunoblots were probed using an antibody to the HA epitope tag,
and were then optically scanned and the digitized images quantitated us-
ing NIH Image software. The total amount of HA immunoreactivity in
each fraction of the second gradient was expressed as a percentage of the
total HA immunoreactivity in the PNS loaded onto the first gradient, or
as shown in Fig. 9 as
Using secretogranin II (SgII) and 
 
3
 
H-serotonin as markers, fractions 7–10
of the second gradient include the peak of LDCVs. The sum of HA immu-
noreactivity for fractions 7–10 of the second gradient was then normalized
for the recovery of LDCVs as follows:
This measure is similar to a recently described granule targeting index
(Blagoveshchenskaya et al., 1999). Note that the number of fractions col-
lected from one-step and two-step procedures were not identical, and that
LDCVs therefore localize to different fractions.
 
Immunoisolation
 
Magnetic beads conjugated to secondary mouse antibody (Dynal) were
HA immunoreactivity in each fraction
HA immunoreactivity in PNS
------------------------------------------------------------------------------------------- 100, ´
HA immunoreactivity fraction (%)
PNS
----------------------------------------------------------------------------------- .
HA immunoreactivity fraction (%)
PNS
-----------------------------------------------------------------------------------
H
3 [] serotonin in fraction 7–10 of index gradient 
H
3 [] -serotonin in index PNS
---------------------------------------------------------------------------------------------------------------------
H
3 [] serotonin in fraction 7–10 of wild-type gradient
H
3 [] serotonin in wild-type PNS
------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------.
´ 
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coated with antisynaptophysin mouse mAb by incubation overnight in
PBS, pH 7.4, containing 2% FCS (immunoisolation buffer), followed by 4
washes in this buffer. For each reaction, 10 
 
m
 
l bead slurry was added to 30
 
m
 
l PNS and mixed for 1 h at 4
 
8
 
C. After washing in immunoisolation
buffer, the bound material was eluted in 2
 
3
 
 Laemmli sample buffer, sub-
jected to Western analysis in parallel with samples of starting material di-
luted to yield images of comparable intensity, and quantitated using
Adobe Photoshop and NIH image. We then expressed the amount of
VAChT in the immunoisolated material as a fraction of the amount of
VAChT in the starting material.
 
Immunoelectron Microscopy
 
Undifferentiated PC12 cells were fixed for 2 h at room temperature with a
mixture of 2% formaldehyde and 0.2% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.4, and stored in 4% formaldehyde until further processing.
Ultrathin cryosectioning was performed according to the method de-
scribed by Liou et al. (1996) and double immunogold labeling as described
by Slot et al. (1991). Labeling was carried out with the polyclonal antibody
to VAChT, which labeled only PC12 cells overexpressing wild-type or
mutant VAChT. For double-labeling with synaptophysin, we used a poly-
clonal rabbit antiserum (Synaptic Systems). Semiquantitative analysis of
the relative subcellular distributions of the S480A and S480E mutants was
performed in double-blind experiments. To establish the percentage of to-
tal label that was present on LDCVs, sections were scanned along a fixed
track and the gold particles associated with LDCVs determined as a pro-
portion of all gold particles no more than 25 nm from a membrane. In a
separate measurement, we used a similar approach to determine the asso-
ciation of gold particles with LDCVs relative to the association with 
 
z50-
nm vesicles. The latter category includes SLMVs, but may also include
Golgi-derived vesicles and constitutively recycling vesicles of a similar
size. For all quantitations, 1,000 gold particles were counted in ten sepa-
rate counting sessions using at least two independently labeled grids.
Results
We first used heterologous expression in COS cells to de-
termine whether VAChT undergoes regulation by phos-
phorylation. Like the VMATs, VAChT sorts to endocytic
vesicles in these cells (Liu et al., 1994; Liu and Edwards,
1997a) and the acidic nature of this compartment supports
the transport activity observed in biochemical studies (Liu et
al., 1992). To facilitate the analysis, we previously engi-
neered an epitope from HA into the lumenal loop between
TMDs 1 and 2 of VAChT, as well as VMAT2. These epitope
tags do not interfere with the transport activity or subcellular
localization of either transporter (Tan et al., 1998).
Phosphorylation of VAChT on Ser-480
To assess the phosphorylation of VAChT, we used meta-
bolic labeling with 32Pi. Immunoprecipitation with an HA
antibody of COS cells labeled continuously with 32Pi for 4 h
shows a prominent labeled protein of z70 kD in cells tran-
siently transfected with the VAChT cDNA (Fig. 1 B,
right). The strongly labeled protein corresponds to the
largest immunoreactive species of VAChT observed in
transfected cells by Western analysis with an antibody to
VAChT (Fig. 1 B, left). An z50-kD immature form of
VAChT (Liu and Edwards, 1997a) and an z35-kD immu-
noreactive species undergo phosphorylation to a lesser ex-
tent (Fig. 1, B and D). The amount of protease inhibitors
used to prepare the cell extracts influences the amount of
the  z35-kD form, suggesting that it results from pro-
teolytic degradation (data not shown), but we have used
the optimal cocktail of protease inhibitors for these exper-
iments, and not observed substantial variation in the re-
covery of full length VAChT. Recognition by the COOH-
terminal antibody to VAChT, but not the more NH2-ter-
minal antibody to the HA tag suggests that the z35-kD
species represents a phosphorylated COOH-terminal frag-
ment (compare Figs. 1 B and 2 A). The analysis of
VMAT2–VAChT chimeras further supports localization
of a phosphorylation site(s) to the COOH terminus (data
Figure 1. Phosphorylation of VAChT on Ser-480 in COS cells. A,
Alignment of the sequences surrounding the dileucine motifs
(underlined) in the COOH termini of VMAT1, VMAT2, and
VAChT. All three transporters show a glutamate at position 24
relative to the dileucine motif. The VMATs also contain a
glutamate at the 25 position. In contrast, VAChT contains a
serine at the equivalent position, serine 480 (Ser-480), sur-
rounded by several arginines that form a consensus sequence for
phosphorylation by PKC and other basic residue-directed ki-
nases (Pearson and Kemp, 1991). B, Phosphorylation of VAChT
in COS cells. Using COS cells transiently transfected with the
cDNA encoding VAChT (1) or no DNA (2), the left shows
Western analysis with a rabbit antibody to VAChT. In the right,
cells metabolically labeled with 32Pi were immunoprecipitated
with the same VAChT antiserum. Of the z70-kD (black
bracket), z50-kD (arrowhead), and z35-kD immunoreactive
species (gray bracket), VAChT undergoes phosphorylation pre-
dominantly on the z70-kD form. The z50-kD species and the
z35-kD doublet appear to undergo less prominent labeling. In
the case of the z35-kD species, the reduced labeling results at
least partly from the inefficiency of immunoprecipitation (data
not shown). C, Phosphoamino acid analysis of VAChT. Immuno-
precipitated VAChT was excised from the gel, hydrolyzed in hy-
drochloric acid, and the hydrolysate separated by thin-layer elec-
trophoresis, using pH 1.9 for the first dimension and pH 3.5 for
the second dimension. Autoradiography shows radiolabeled ma-
terial comigrating with the phosphoserine (P-Ser) standard, but
not with the phosphothreonine (P-Thr) or phosphotyrosine
(P-Tyr) standards. Phosphopeptides resulting from incomplete
hydrolysis migrate as a smear in the second dimension. Free 32Pi
migrates at the position shown (Pi), and the origin is circled. D,
VAChT undergoes phosphorylation on Ser-480. COS cells tran-
siently transfected with cDNAs encoding wild-type VAChT (wt),
with mutant cDNAs containing alanine replacements at Ser-478,
Ser-480, or with no DNA (2) were metabolically labeled with
32Pi, immunoprecipitated with the VAChT antibody, and sub-
jected to SDS-PAGE, followed by autoradiography. Mutation of
Ser-480, but not Ser-478, reduced phosphorylation of the mature
form of VAChT (black bracket) and the COOH-terminal frag-
ment (gray bracket). Molecular weight markers (kD) are shown
to the left in B and D.Krantz et al. VAChT Sorting to LDCVs 383
not shown). Since the COOH terminus of VAChT con-
tains serine, threonine, and tyrosine residues that might
serve as phosphorylation sites, we performed phospho-
amino acid analysis of the VAChT protein expressed in COS
cells and metabolically labeled with 32Pi (Boyle et al.,
1991). Hydrolysates of immunoprecipitated VAChT con-
tain phosphoserine, but not phosphothreonine or phos-
photyrosine residues, indicating that phosphorylation of
VAChT occurs exclusively on serine (Fig. 1 C).
Although the COOH terminus of VAChT contains sev-
eral serine residues, we have focused on Ser-478 and -480
(Fig. 1 A). Both of these residues show strong conserva-
tion in vertebrates (Erickson et al., 1994; Roghani et al.,
1994; Naciff et al., 1997) and reside within a consensus se-
quence for phosphorylation by multiple kinases including
PKC (Pearson and Kemp, 1991). In addition, Ser-480 oc-
curs five residues upstream from the dileucine motif re-
quired for efficient internalization of VAChT from the
plasma membrane (Tan et al., 1998) and the VMATs con-
tain a highly conserved glutamate at the equivalent posi-
tion (Liu et al., 1992; Erickson and Eiden, 1993; Krejci et
al., 1993). Further, an acidic residue at the 25 position rel-
ative to a dileucine motif influences the sorting of other
membrane proteins (Pond et al., 1995) and phosphoryla-
tion at this position regulates the trafficking of CD3g and
CD4 (Shin et al., 1991; Dietrich et al., 1994). To determine
whether VAChT undergoes phosphorylation on Ser-480
or Ser-478, we used site-directed mutagenesis (Kunkel et
al., 1991) to replace these residues individually with ala-
nine. Metabolic labeling and immunoprecipitation of the
mutants expressed in COS cells shows reduced phosphory-
lation of the S480A, but not the S478A mutant (Fig. 1 D).
Although the S480A mutant shows low levels of residual
phosphorylation on the z70-kD species, the mutation
eliminates labeling of the COOH-terminal z35-kD frag-
ment (Fig. 1 D, also see 2 A). Simultaneous mutagenesis of
both Ser-478 and Ser-480 did not further reduce the phos-
phorylation (data not shown). Thus, the COOH terminus
of VAChT appears to undergo phosphorylation predomi-
nantly, if not solely, on Ser-480.
To extend the analysis of VAChT phosphorylation to
neuroendocrine cells, we used heterologous expression in
rat pheochromocytoma PC12 cells. Metabolic labeling
with  32Pi of PC12 transformants stably expressing VAChT
shows prominent labeling of an z70-kD band not ob-
served in untransfected cells (Fig. 2 A, right). As in COS
cells, the S480A mutation greatly reduces the labeling of
both this band and the z35-kD species, and Western anal-
ysis of the cell extracts confirms the equivalent expression
of both wild-type and mutant VAChT (Fig. 2 A, left).
Thus, phosphorylation of the VAChT COOH terminus
occurs on Ser-480 in both COS and PC12 cells.
Regulation by PKC
To determine whether VAChT phosphorylation under-
goes regulation, we have pharmacologically stimulated
several protein kinases in the stably transfected PC12 cells.
Using the calcium ionophore A23187 in the presence of
external calcium to activate such calcium-dependent ki-
nases as CaMKII and facilitate phosphorylation by cal-
cium-dependent (conventional) isoforms of PKC (cPKC),
we found an increase in phosphorylation of VAChT (Fig.
2 B, lane 2) relative to untreated cells (Fig. 2 B, lane 1).
Stimulation of cPKC and other PKC isoforms with the
phorbol ester phorbol 12,13-diacetate (PDA) activates
VAChT phosphorylation even more strongly (Fig. 2 B,
lane 3). In contrast, stimulation of cAMP-dependent
protein kinase (PKA) with the cell-permeable cAMP
analogue 8-bromo-adenosine 39,59-cyclic monophosphate
(8-Br-cAMP) modestly inhibits VAChT phosphorylation.
These results suggest phosphorylation of VAChT by PKC,
Figure 2. Phosphorylation of VAChT by
PKC in PC12 cells. A, Untransfected PC12
cells (2), cells stably expressing HA-
tagged wild-type VAChT (wt), and cells
expressing mutant VAChT with an alanine
replacement at Ser-480 (S480A) were met-
abolically labeled with 32Pi, immunopre-
cipitated with an antiserum against VAChT,
and subjected to SDS-PAGE, followed by
autoradiography (right), or blotted to ni-
trocellulose and immunostained with an
mAb to the HA tag (left). The mature
z70-kD and the z35-kD doublet forms of VAChT undergo phosphorylation (see arrowheads). Substitution of Ser-480 by alanine re-
duces phosphorylation of the z70-kD form and eliminates phosphorylation of the z35-kD doublet without affecting the levels of the
mature VAChT protein (left). Note that the mAb to HA does not recognize the z35-kD doublet as seen in the immunoblot, presum-
ably because these species are COOH-terminal fragments that do not contain the more NH2-terminal HA tag. B, Regulation of VAChT
phosphorylation. PC12 cells stably expressing wild-type HA-tagged VAChT were metabolically labeled for 4 h with 32Pi, treated for 15
min with vehicle alone (DMSO; lane 1), 10 mM A23187 (lane 2), 3 mM phorbol diacetate (PDA; lane 3), or 1 mM 8-bromo-cyclic AMP
(cAMP) with 1 mM of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (lane 4), and the extracts either immunoprecipi-
tated for VAChT (top), or transferred to nitrocellulose and immunostained for HA (bottom). VAChT shows a robust increase in phos-
phorylation with PDA, and a smaller increase in phosphorylation with A23187. A small decrease in phosphorylation occurs with in-
creased cAMP (lane 4). C, Regulation of Ser-480 phosphorylation. PC12 cells stably expressing wild-type HA-tagged VAChT (lanes 1
and 2) and cells expressing mutant VAChT with an alanine replacement at Ser-480 (S480A; lanes 3 and 4) were metabolically labeled
with 32Pi, treated for 15 min with vehicle alone (2; lanes 1 and 3) or 3 mM phorbol diacetate (PDA; lanes 2 and 4) and immunoprecipi-
tated as in B. Replacement of Ser-480 with alanine greatly reduces PDA-induced phosphorylation of VAChT.The Journal of Cell Biology, Volume 149, 2000 384
with the potential for modulation by other signaling path-
ways. Mutagenesis of Ser-480 dramatically reduces PDA-
induced changes in VAChT phosphorylation (Fig. 2 C),
indicating that Ser-480 undergoes PKC-dependent phos-
phorylation.
To identify the kinase(s) responsible for phosphorylating
VAChT, we have extended the analysis in vitro. As a sub-
strate for phosphorylation, we produced a bacterial protein
containing GST fused to the COOH terminus of VAChT
(GST-VAChT). Since phosphorylation in vitro may show
less specificity than in intact cells, we first tested the speci-
ficity of GST-VAChT phosphorylation. In the presence of
g[32P]ATP and COS or PC12 cell lysate, GST-VAChT un-
dergoes robust phosphorylation (Fig. 3, A and E). The
replacement of Ser-480, but not Ser-478 with alanine
abolishes this modification, consistent with the results of
metabolic labeling in intact cells and indicating the specific-
ity of in vitro phosphorylation for the appropriate residues
(Fig. 3, A and E). Similar to the changes observed in cells
with the calcium ionophore A23187, addition of Ca21 to
the in vitro reaction increases phosphorylation of the fu-
sion protein (Fig. 3, B and E). Calmodulin does not further
alter the response to increased Ca21, consistent with data
from intact cells implicating Ca21-dependent isoforms of
PKC, which do not require calmodulin for activation.
We used the in vitro phosphorylation reaction and spe-
cific inhibitors to identify the kinase(s) responsible for
phosphorylating VAChT. The PKC inhibitor H7 partially
blocks VAChT phosphorylation by COS (Fig. 3, C and D)
or PC12 (Fig. 3 E) cell extracts, but H7 also inhibits such
other kinases as PKA (Hidaka et al., 1984). We tested the
effect of bisindolylmaleimide I (BIS), a highly specific
PKC inhibitor (Ki z0.01 mM) that inhibits other kinases
only at much higher concentrations (Ki for PKA z2 mM;
Toullec et al., 1991). BIS inhibits phosphorylation of
VAChT by z50% at 0.1 mM, implicating PKC in VAChT
phosphorylation. Increasing concentrations of BIS do not
further reduce phosphorylation, suggesting that distinct ki-
nase(s) may also contribute to VAChT phosphorylation.
However, both peptide and nonpeptide inhibitors of PKA
(H89; Chijiwa et al., 1990) and CamKII (KN93; Sumi et
al., 1991) do not inhibit VAChT phosphorylation at con-
centrations that selectively inhibit these enzymes (data not
shown). Thus, although the identity of the additional ki-
Figure 3. In vitro phosphorylation of VAChT on Ser-480. A,
Phosphorylation of wild-type and mutant VAChT bacterial fu-
sion proteins. Fusion proteins containing GST joined in frame to
the COOH terminus of wild-type VAChT (wt) or VAChT mu-
tants with alanine replacements at Ser-478, Ser-480, or both Ser-
478 and Ser-480 (478/480) were incubated with g[32P]ATP and a
postnuclear COS cell supernatant for 20 min at 308C. The pro-
teins were then separated by electrophoresis and submitted to
autoradiography. The fusion protein containing wild-type
VAChT showed robust phosphorylation. Mutation of Ser-480 or
both Ser-478/480, but not Ser-478 alone eliminates phosphoryla-
tion. Staining with Coomassie blue showed similar levels of fu-
sion protein in each lane (data not shown). B, Calcium increases
VAChT phosphorylation. Wild-type VAChT fusion proteins
were incubated as in A with and without 2 mM calcium chloride,
and 2.4 mM calmodulin. The addition of calcium potentiates
VAChT phosphorylation, implicating a calcium-activated kinase.
C, PKC inhibitors reduce VAChT phosphorylation. Wild-type
VAChT fusion proteins were incubated as in A, but with the con-
centration of ATP lowered to 1 mM to reduce competition with
kinase inhibitors. The PKC-selective inhibitor H7 (final concen-
tration 6 or 60 mM), and the more PKC-specific BIS (final con-
centration 0.1 or 1 mM) or vehicle (2) were added before the ly-
sate and g[32P]ATP. Coomassie blue staining confirmed the
presence of similar amounts of fusion protein in each lane (bot-
tom). D, Quantitative analysis of PKC inhibition. Autoradio-
graphs of the kind shown in D were optically scanned, the digital
images quantitated, and the values expressed as a percentage of
samples treatment with vehicle alone (percent control). The av-
erage  6 standard error of two independent experiments are
shown. E, Phosphorylation of VAChT bacterial fusion proteins
using PC12 cell lysate. Fusion proteins containing the COOH ter-
minus of wild-type VAChT (lanes 1–7) or the VAChT mutant
with an alanine replacement at Ser-480 (lane 8) were incubated
with g[32P]ATP and a postnuclear PC12 cell supernatant for 20
min at 308C with or without addition of the PKC inhibitors H7 or
BIS, as described in C (lanes 1–5), or 2 mM calcium chloride
(lanes 6 and 7). Coomassie blue staining confirmed the presence
of similar amounts of fusion protein (bottom). F, Phosphoryla-
tion of VAChT bacterial fusion proteins by purified PKC. Fusion
proteins containing wild-type VAChT (wt) or VAChT mutants
with alanine replacements at Ser-480 or both Ser-478 and Ser-480
(478/480), or histone H1 as a positive control were incubated with
g[32P]ATP and the catalytic fragment of PKC for 20 min at 308C.
Similar to histone H1, the fusion protein containing wild-type
VAChT shows robust phosphorylation. Mutation of Ser-480, or
both Ser-478 and Ser-480, eliminates phosphorylation by PKC.Krantz et al. VAChT Sorting to LDCVs 385
nases remains unclear, the effects of calcium, PDA, and
BIS on VAChT phosphorylation suggest that a calcium-
and diacylglycerol-activated form of PKC mediates phos-
phorylation of the transporter at Ser-480. Indeed, purified
PKC robustly phosphorylates Ser-480 in vitro (Fig. 3 F).
These results are consistent with a previous report show-
ing that VAChT undergoes PKC-dependent phosphoryla-
tion in synaptosomes prepared from hippocampus (Bar-
bosa et al., 1997).
Ser-480 and VAChT Localization
Previous structural analysis of the VMATs and VAChT
has implicated the central region containing 12 TMDs in
the translocation of substrate (Merickel et al., 1995; Finn
and Edwards, 1998). In contrast, the COOH termini ap-
pear to be required for localization rather than transport
(Tan et al., 1998). Nonetheless, we compared the ACh
transport activity of PC12 cells expressing the wild-type
protein with that of cells expressing the S480A mutant and
a mutant in which Ser-480 was replaced by glutamate to
mimic the phosphorylation event (S480E). Using a stan-
dard transport assay, the activities of the S480A and
S480E mutants were similar to wild-type (data not shown),
suggesting that phosphorylation of Ser-480 does not affect
catalytic function.
Since COOH-terminal signals appear to govern the mem-
brane trafficking of VMATs and VAChT (Tan et al., 1998;
Varoqui and Erickson, 1998), we have focused on the possi-
ble role of phosphorylation at Ser-480 on the localization of
VAChT using transfected PC12 cells stably expressing wild-
type and mutant proteins. After treatment with nerve
growth factor to induce neurite formation, double-staining
shows extensive colocalization of wild-type VAChT with
the endosome/SLMV marker synaptophysin in both the cell
body and at the tips of processes (Liu and Edwards, 1997a;
Fig. 4). To determine the role of phosphorylation in the
localization of the wild-type protein, we used PDA to
stimulate PKC, and tautomycin (100 nM) to inhibit pro-
tein phosphatases 1 and 2A, and observed a decrease in
the perinuclear localization of wild-type VAChT (data
not shown). However, the S480A mutant showed similar
changes in localization after treatment with PDA and tauto-
mycin, excluding a role for phosphorylation at this site in
Figure 4. Mutation of Ser-480
influences localization of VAChT
to endosomes and SLMVs. PC12
cells stably expressing HA-
tagged wild-type VAChT, the
S480A and S480E mutants were
double-stained with a mouse
mAb to HA (a, d, and g), and
a rabbit polyclonal antibody
to synaptophysin (syn; b, e, and
h), a marker for endosomes
and synaptic-like microvesicles
(SLMVs). Visualized with the ap-
propriate secondary anti-mouse
antibodies conjugated to FITC
(a, d, and g) and anti-rabbit anti-
bodies conjugated to Texas red
(b, e, and h), the cells were ex-
amined by confocal laser mi-
croscopy. The overlays of FITC
and Texas red channels are
shown in c, f, and i. Wild-type
VAChT (a–c) and the S480A
mutant (d–f) extensively, but in-
completely colocalize with syn-
aptophysin in cell bodies and
processes. In contrast, the S480E
mutant (g–i) resides primarily in
processes. Bar, 10 mm.The Journal of Cell Biology, Volume 149, 2000 386
the observed changes. Indeed, PKC and protein phospha-
tases contribute to many membrane trafficking events
(Davidson et al., 1992; De Mattheis et al., 1993). To assess
the specific role of Ser-480 phosphorylation on VAChT lo-
calization, we therefore used mutants that prevent (S480A)
or mimic (S480E) phosphorylation specifically at this site.
The S480A mutant shows similar, extensive colocaliza-
tion with synaptophysin, similar to wild-type VAChT.
However, S480E localizes less with synaptophysin in the
cell body. Rather, the distribution of S480E more closely
resembles that of the LDCV marker SgII than wild-type
VAChT or S480A (Fig. 5). The results suggest that an
acidic residue 25 relative to the dileucine motif influences
the steady-state distribution of VAChT.
To characterize further the effect of Ser-480 mutations
on the membrane trafficking of VAChT, we have used
density gradient fractionation (Liu et al., 1994). As noted
previously, wild-type VAChT partially colocalizes with the
SLMV/endosome marker synaptophysin in light fractions
on equilibrium sedimentation gradients. However, VAChT
localizes to additional compartments including LDCVs,
and appears as a relatively broad peak extending into
heavier fractions (Liu and Edwards, 1997a; Varoqui and
Erickson, 1998). HA-tagged VAChT shows a similar dis-
tribution (Fig. 6 A). The S480A mutant also appears pref-
erentially in light fractions (Fig. 6 B), and exhibits a single
peak that coincides more precisely with the peak of synap-
tophysin than does wild-type VAChT. The S480E mutant,
which mimics phosphorylation at Ser-480, also comigrates
with synatophysin. However, S480E shows increased co-
fractionation with heavier membranes relative to wild-type
VAChT and the S480A mutant (Fig. 6, C and D), confirm-
ing that an acidic residue at position 25 relative to the
dileucine motif influences subcellular localization.
The immunofluorescence and fractionation experiments
suggest that the Ser-480 mutations also change the expres-
sion of VAChT on SLMVs and/or endosomes. To further
quantitate these differences, we immunoisolated vesicles
expressing synaptophysin from cells expressing wild-type
and mutant VAChT, and determined the amount of im-
munoreactive VAChT in synaptophysin-positive (syn1)
vesicles relative to the total amount in cell lysates (Fig. 6
E). The S480A mutant sorts to syn1 vesicles in proportions
similar to wild-type VAChT (z15%). The low proportion
presumably reflects the localization of VAChT to multiple
membrane compartments, suggested by the distribution
on sucrose gradients, as well as, perhaps, the inefficiency
of immunoisolation. In contrast to the wild-type protein
and S480A, the S480E mutant localizes to syn1 vesicles in
lower proportions (z7%). Since synaptophysin resides on
both endosomes and SLMVs in PC12 cells, the results in-
dicate reduced expression of S480E on one or both of
these membranes. To determine whether the Ser-480 mu-
tations specifically affect sorting to SLMVs, we separated
endosomes from SLMVs using velocity gradient sedimen-
tation. However, we did not detect consistent differences
in the proportion of wild-type and mutant VAChT ex-
pressed on SLMVs (data not shown), suggesting that the
increase in targeting of S480E to heavy fractions on su-
crose density gradients correlates primarily with a de-
crease in localization to syn1 endosomes.
Altered Localization of a VMAT2 Mutant
Unlike VAChT, wild-type VMAT2 contains acidic resi-
dues at both positions 24 and 25 relative to the dileucine-
like motif (Glu-478 and Glu-479; see Fig. 1). The impor-
tance of acidic charge upstream of the dileucine motif in
Figure 5. Mutation of Ser-480 al-
ters the localization of VAChT
to process tips. PC12 cells stably
expressing wild-type VAChT,
S480A, and S480E mutants were
double-stained with a mouse
mAb to the epitope tag (HA; a,
d, and g), and a rabbit polyclonal
antiserum to SgII (b, e, and h), a
marker for LDCVs. Visualized
with the appropriate secondary
anti-mouse antibodies conjugated
to FITC (a, d, and g) and anti-
rabbit antibodies conjugated to
Texas red (b, e, and h), the cells
were examined by confocal mi-
croscopy. The overlays of FITC
and Texas red channels are
shown in c, f, and i. Wild-type
VAChT (a–c) and S480A (d–f)
partially colocalize with SgII at
the tips of processes, but also oc-
cur at high levels in cell bodies.
In contrast, S480E (g–i) colocal-
izes extensively with SgII in the
tips of processes, and like SgII,
shows less expression in cell bod-
ies. Bar, 10 mm.Krantz et al. VAChT Sorting to LDCVs 387
Figure 6. Density gradient fractionation of wild-type and mutant VAChT. PNSs of PC12 cells stably expressing HA-tagged wild-type
VAChT (A), and mutants S480A (B) and S480E (C), were separated by equilibrium gradient centrifugation through 0.65–1.55 M su-
crose. The fractions were submitted to Western analysis with the mAb to HA for VAChT (top of immunoblots in A, B, and C), a poly-
clonal antibody to the LDCV marker SgII (middle), and an mAb to the endosome/SLMV marker synaptophysin (syn; bottom). The
gradients shown in A–C were digitized and quantified. For each fraction, the amount of HA-tagged VAChT, synaptophysin, and SgII
was expressed as a percentage of the total immunoreactivity shown to the left of the immunoblots. Consistent with previous results (Liu
and Edwards, 1997a), wild-type VAChT partially cofractionates with synaptophysin as a broad peak that also overlaps with fractions
containing SgII. In contrast, S480A cofractionates well with synaptophysin. The mutant S480E mutant, on the other hand, fractionates
with synaptophysin, but also shows a second peak that cofractionates with SgII in heavy fractions. D, The ratio of HA-tagged VAChT
localized to light fractions 6–8 (left) or heavy fractions 11 and 12 (right) were expressed as a percentage of total HA immunoreactivity.
The mean 6 standard error (n 5 3) were derived from the data shown in A–C, together with additional experiments using two indepen-
dently derived cell lines for each mutant. E, Immunoisolation of synaptophysin-containing vesicles. PNSs from cell lines expressing
wild-type VAChT, and the S480A and S480E mutants, were incubated with magnetic beads conjugated with an mAb to synaptophysin.
Western blots of immunoisolated synaptophysin positive (syn1) vesicles and starting lysate (start) were then immunostained using a
polyclonal antiserum to VAChT. The amount of immunoisolated VAChT relative to the starting material was determined from digi-
tized images and expressed as syn1/start. The average 6 SEM were determined from two independent experiments. Similar proportions
of wild-type of S480A localize to syn1 membranes, whereas the S480E mutant localizes approximately half as well, indicating the impor-
tance of a neutral residue at Ser-480 for sorting to light vesicles.The Journal of Cell Biology, Volume 149, 2000 388
VAChT suggests that Glu-478 and Glu-479 may also affect
VMAT2 trafficking. We therefore replaced Glu-478 and
-479 with alanine (E478A/E479A). Immunofluorescence
of stably transfected PC12 cells shows that wild-type
VMAT2 colocalizes with the LDCV marker SGII at the
tips of processes (Fig. 7, a–c). However, the E478A/E479A
mutant differs from SGII and shows consistently strong la-
beling in cell bodies (Fig. 7, d–f). Indeed, the E478A/
E479A mutant colocalizes with synaptophysin to a greater
extent than wild-type VMAT2 (Fig. 7, g–l). Thus, acidic
residues upstream of the dileucine motif appear to be im-
portant for the localization of VMAT2, as well as VAChT.
VMATs localize almost exclusively to LDCVs in PC12
cells, and therefore cofractionate to a high degree with
SGII in the heavy fractions of sucrose equilibrium sucrose
gradients (Liu et al., 1994). Increased localization of the
VAChT mutant S480E to heavy fractions suggests that
neutralization of Glu-478 and Glu-479 might conversely
reduce the localization of VMAT2 to LDCVs. HA-tagged
VMAT2 cofractionates nearly identically with SGII, con-
sistent with its localization to LDCVs (Fig. 8 A). In con-
trast, the E478A/E479A mutant cofractionates with SgII
to a lesser extent, and the profile of VMAT2 immunoreac-
tivity across the gradient differs greatly from that of the
LDCV marker (Fig. 8 B). Since wild-type VMAT2 resides
almost entirely on LDCVs, these results indicate that neu-
tralization of Glu-478 and -479 reduces the proportion of
VMAT2 expressed on LDCVs. Acidic residues upstream
of the dileucine motif in VMAT2 thus influence sorting of
the transporter to this population of regulated secretory
vesicles.
S480E Increases VAChT Sorting to LDCVs
Replacement of Ser-480 to mimic phosphorylation redis-
tributes VAChT to the tips of processes in PC12 cells, and
to heavier fractions in density gradients. To determine
whether the S480E mutation specifically increases local-
ization of VAChT to LDCVs, we have used additional
membrane fractionation and immunoelectron microscopy
to assess the localization of the S480E mutant to LDCVs.
A two-step fractionation procedure involving velocity
sedimentation, followed by equilibrium sedimentation
(Stinchcombe and Huttner, 1994), separates LDCVs from
other membranes of similar size and density. A small per-
centage of wild-type (Liu et al., 1994) and HA-tagged
VAChT (z4.5%) resides on LDCVs (Fig. 9). However,
mutations at Ser-480 change the amount of HA-tagged
VAChT in LDCV fractions relative to the amount of
transporter in starting material loaded onto the first ve-
locity gradient (Fig. 9). The S480A mutant localizes to
LDCVs to a slightly lesser extent (z3.4%), and the
S480E mutation increases expression on LDCVs to z10.6%,
2.3-fold more than wild-type, and about threefold more
than the S480A mutant. The low proportion of VAChT on
LDCVs, even in the case of the S480E mutant may reflect
the inefficiency of the two-step procedure, which results in
more highly purified LDCVs at the expense of yield.
Figure 7. Neutralization of
glutamates-478 and -479 in
VMAT2. To eliminate the nega-
tive charge upstream of the di-
leucine motif in VMAT2, Glu-478
and -479 were replaced by ala-
nine. PC12 cells stably express-
ing wild-type VMAT2 and the
E478A/E479A mutant (EE/AA)
were double-stained with a
mouse mAb to the HA epitope
(a, d, g, and j) and either a rabbit
polyclonal antiserum to SgII (b
and e), or a rabbit antibody to
synaptophysin (syn; h and k).
Secondary anti-mouse antibod-
ies conjugated to Cy3 (a, d, g,
and j) or anti-rabbit antibodies
conjugated to Cy5 (b, e, h, and
k) were used to visualize the
proteins, and the cells were ex-
amined by confocal microscopy.
The overlay of Cy3 and Cy5 im-
ages are shown in c, f, i, and l.
Wild-type VMAT2 colocalizes
with both SgII and synaptophysin
at the tips of cell processes, but
does not colocalize with synap-
tophysin at cell bodies. In con-
trast, the EE/AA mutant resides
at high levels in cell bodies and
exhibits greater colocalization
with synaptophysin than wild-
type VMAT2. Bars, 10 mm.Krantz et al. VAChT Sorting to LDCVs 389
Nonetheless, the S480A mutation modestly reduces, and
the S480E mutation clearly increases, the expression of
VAChT on LDCVs, indicating that an acidic residue at
position 480 increases localization of VAChT to LDCVs,
and suggesting that a negatively charged phosphoserine at
this position in wild-type VAChT may similarly direct the
transporter to LDCVs.
The subcellular location of wild-type VAChT, as well as
the S480A and S480E mutants, was analyzed in more de-
tail by immunogold labeling of ultrathin cryosections (Fig.
10). LDCVs in PC12 cells appear in cryosections as 75–
125-nm diam compartments with an electrodense core
(Fig. 10 E) that labels for SgII (not shown). In agreement
with previous observations, wild-type VAChT localizes to
LDCVs, as well as numerous small vesicular profiles found
in the area near the Golgi complex (Fig. 10 A), near endo-
somes (Fig. 10 B), or on membranes dispersed throughout
the cytoplasm (Weihe et al., 1996; Liu and Edwards,
1997a; Fig. 10 C). Label was also found directly over the
Golgi complex, plasma membrane, and endosomes. Dou-
ble-labeling shows that VAChT and synaptophysin colo-
calize to a high degree in the small vesicular profiles (Fig.
10 C) which largely represent the SLMVs of PC12 cells (de
Wit et al., 1999). VAChT appears in early endosomes as
well, characterized by a limited number of internal mem-
branes (Fig. 10 B), but is absent from densely filled late
Figure 8. The E478A/E479A mutation redistributes VMAT2 away from LDCVs. PNSs of PC12 cells stably expressing HA-tagged wild-
type VMAT2 and the E478A/E479A (EE/AA) mutant were separated by equilibrium sedimentation through 0.6–1.6 M sucrose. The
fractions were analyzed by Western blot using a monoclonal HA antibody for VMAT2 (top of immunoblots in A and B), a polyclonal
antibody to SgII (middle), and an mAb to synaptophysin (bottom). The immunoblots shown in A and B were digitized, quantified, and
the amounts of HA-tagged VMAT2, synaptophysin, and SgII was expressed as a percentage of total immunoreactivity. Wild-type
VMAT2 cofractionates more strongly with SgII than with synaptophysin. In contrast, the EE/AA mutation shifts VMAT2 into lighter
membrane fractions. D, The proportion of VMAT2 localized to light fractions 6–8 (left) or heavy fractions 11–12 was expressed as a
percentage of total VMAT2 immunoreactivity across the gradients, using the data shown in A–C and two additional independently iso-
lated cell lines for each mutant. The bar graph shows the mean 6 standard error (n 5 3).The Journal of Cell Biology, Volume 149, 2000 390
endosomes and lysosomes (Fig. 10 A). Notably, the limit-
ing membrane of the vacuolar part of early endosomes
(also known as the sorting endosome) contains relatively
little VAChT label, whereas dense labeling appears over
surrounding vesicles. A similar steady-state distribution
over early endosomes has previously been shown for syn-
aptophysin (Clift-O’Grady et al., 1990; Cameron et al.,
1991; Regnier-Vigouroux et al., 1991) and implies rapid
sorting of proteins into recycling vesicles.
The S480A and S480E mutants label the same compart-
ments as wild-type VAChT (Fig. 10, D and E), but with
different relative distributions. Of all the gold particles
present in a section, 17.5% S480A and 29.4% S480E ap-
pear over the membrane of LDCVs (Table I). In addi-
tion, when the distribution of gold particles between only
LDCVs and SLMVs was quantitated, 40% S480A and 56%
S480E were found over LDCVs (Table I). Consistent with
the immunofluorescence and biochemical fractionation, im-
munoelectron microscopy thus provides quantitative evi-
dence for the increased localization of S480E to LDCVs.
Discussion
In addition to differences in their contents, subcellular lo-
cation and mode of release, LDCVs and SVs differ in their
biogenesis (Bauerfeind and Huttner, 1993; Kelly, 1993;
Martin, 1994). Electron microscopic observations have in-
dicated that LDCVs bud directly from the trans-Golgi net-
work (TGN; Farquhar et al., 1978; Tooze and Tooze, 1986;
Orci et al., 1987). After a maturation process that involves
the removal of proteins destined for other intracellular
membranes (Tooze et al., 1991; Klumperman et al., 1998),
LDCVs undergo regulated exocytosis. In contrast, SVs do
not form at the TGN. Rather, proteins destined for SVs
sort to constitutive secretory vesicles at the TGN, arrive at
the plasma membrane in the absence of stimulation, and
enter SVs only after recycling from the cell surface (Clift-
O’Grady et al., 1990; Cameron et al., 1991; Regnier-
Vigouroux et al., 1991). However, relatively little is known
about the signals that sort proteins to either LDCVs or
SVs (Grote et al., 1995; Haucke and De Camilli, 1999).
Previous studies of protein sorting to LDCVs have fo-
cused on their soluble contents. Although recent work has
Figure 9. Localization of wild-type and mutant VAChT to LDCVs.
PNSs of PC12 cells stably expressing wild-type VAChT (wt), and
S480A and S480E mutants preloaded with [3H]serotonin were
separated on a sucrose velocity gradient, the peak LDCV frac-
tions determined by scintillation counting, pooled, and separated
again by equilibrium sedimentation through sucrose. The frac-
tions were immunoblotted with an mAb to the HA tag and the
amount of HA immunoreactivity in each fraction of the second
gradient was quantified and expressed as a proportion of immu-
noreactivity in the starting material (PNS) loaded onto the first
gradient (A). The peak of HA immunoreactivity on the second
density gradient coincides with that of the LDCV marker SgII
(B), and with the peak of [3H]serotonin (not shown). The aver-
age 6 SEM was determined from two independently isolated cell
lines for each mutant (C). S480E localizes to LDCVs z2.3-fold
and threefold better than wild-type VAChT and the S480A mu-
tant, respectively.
Table I. Distribution of S480A and S480E VAChT to
Secretory Vesicles
A. Localization of gold particles to LDCVs
Mutant LDCV/total
%
S480A 17.5 6 3
S480E 29.4 6 2.7
B. Relative distribution of particles to LDCVs versus SLMVs
Mutant LDCVs/(LDCVs 6 SLMVs)
%
S480A 40.3 6 1.6
S480E 55.9 6 2.5
In immunogold-labeled ultrathin cryosections, the number of gold particles representing
VAChT mutants S480A and S480E, over LDCVs, SLMVs, and other compartments was
counted blindly. The percentage of VAChT localized to LDCVs relative to the total
counted particles (A) and the percentage of gold particles found over either LDCVs
relative to the sum of particles over LDCVs plus SLMVs (B) are indicated in the table.Krantz et al. VAChT Sorting to LDCVs 391
implicated the processing enzyme carboxypeptidase E in
sorting to LDCVs (Cool et al., 1997), most neural peptides
sort into LDCVs as a result of aggregation under the par-
ticular redox and pH conditions of nascent LDCVs (Cha-
nat and Huttner, 1991; Rindler, 1998). Thus, the soluble
cargo of LDCVs are not thought to contain a specific sort-
ing sequence, but rather to enter the regulated secretory
pathway as a result of their general biophysical properties.
In contrast, integral membrane proteins of the LDCV
have the potential to interact directly with sorting machin-
ery through their cytoplasmic domains which presumably
contain specific sorting signals.
Most of the integral membrane proteins present on
LDCVs also occur at substantial levels on SVs. These in-
clude the vSNARE proteins involved in vesicle docking and
fusion (Schmidle et al., 1991; Glenn and Burgoyne, 1996), as
well as certain isoforms of the calcium sensor synaptotag-
min (Schmidle et al., 1991; Walch-Solimena et al., 1993).
Heterologous expression in neuroendocrine cells of the
endothelial protein P-selectin also confers expression on
both LDCVs and SVs (Norcott et al., 1996). In contrast,
VMATs localize preferentially to LDCVs in PC12 cells,
indicating that they sort more specifically to the regulated
secretory pathway (Liu et al., 1994). The closely related
VAChT also occurs on LDCVs, but at a much lower level
than the VMATs (Liu and Edwards, 1997a; Varoqui and
Erickson, 1998). VAChT preferentially localizes to lighter
membranes, including endosomes and SLMVs in PC12
cells, indicating substantial differences in trafficking from
the VMATs. Recent observations also indicate that the
differential trafficking of the transporters depends on sig-
nals contained in their cytoplasmic, COOH-terminal do-
mains (Tan et al., 1998; Varoqui and Erickson, 1998).
Using a combination of immunofluorescence, biochemi-
cal fractionation, and immunoelectron microscopy, we
now show that mutation of Ser-480 regulates membrane
trafficking of VAChT to LDCVs. By immunofluores-
cence, the distribution of wild-type and the S480A mutant
protein resembles that of synaptophysin. In contrast, the
localization of S480E differs from wild-type VAChT and
S480A, and more closely resembles that of the LDCV
marker SGII. Equilibrium sedimentation through sucrose
also reveals a larger proportion of S480E than wild-type
VAChT in heavy fractions, comigrating with LDCVs.
Mutation of acidic residues upstream of the dileucine
motif in VMAT2 (Glu-478 and -479) also alters trans-
porter localization. However, unlike VAChT, wild-type
VMATs localize almost exclusively to LDCVs (Liu et al.,
1994). The effect of VAChT mutations at Ser-480 suggest
that neutralization of glutamate residues upstream of the
dileucine motif in VMAT2 might reduce localization to
LDCVs. Indeed, immunofluorescence and sucrose equi-
librium gradients show that replacement of Glu-478 and
-479 by alanine partially redistributes VMAT2 to lighter
membranes and away from LDCVs. The E478/479A
mutation does not eliminate localization of VMAT2 to
LDCVs, and additional signals may contribute to the sort-
ing of VMAT2. The results nonetheless suggest that acidic
residues upstream of a dileucine motif are involved in the
trafficking of VMAT2 to regulated secretory vesicles.
In addition, two-step fractionation shows that the S480E
mutation increases localization of VAChT to LDCVs rela-
tive to wild-type protein and the S480A mutant. Quantita-
tive immunoelectron microscopy further confirms the in-
creased expression of S480E on LDCVs, although the
difference from S480A appears less marked than the
threefold increase observed by the two-step fractionation
procedure. Losses of starting material during fractionation
may have amplified slightly the difference in localization
between S480A and S480E. Nonetheless, analysis of the
mutants strongly suggests that a negative charge five resi-
dues upstream of the dileucine motif increases the sorting
of VAChT to LDCVs.
Both gradient fractionation and immunoisolation in-
dicate a corresponding decrease in the sorting of S480E
to synaptophysin containing vesicles. However, synapto-
physin localizes to both endosomes and SLMVs in PC12
cells (Clift-O’Grady et al., 1990; Cameron et al., 1991). We
therefore performed velocity gradient fractionation to
specifically determine the effect of S480E on SLMVs.
Since the S480E mutant sorts to SLMVs in proportions
similar to wild-type and S480A, the negative charge up-
stream of the dileucine motif may not influence sorting to
SLMVs, at least in PC12 cells. In neurons, however, synap-
tophysin localizes almost exclusively to SVs, and the domi-
nant pathway of SV biogenesis is likely to differ from that
used in PC12 cells (Shi et al., 1998), leaving open the possi-
bility that phosphorylation of Ser-480 influences the local-
ization to SVs in neurons.
Very few, if any, other signals responsible for localiza-
tion to LDCVs have previously been identified. The pro-
tein P-selectin, which localizes to secretory granules in
endothelial cells and to LDCVs after heterologous expres-
sion in PC12 cells (Norcott et al., 1996), has a sequence at
its cytoplasmic COOH terminus (KDDG) that resembles
the sequence of basic and acidic residues in the VMATs
and VAChT. However, unlike the VMATs and VAChT,
selectin does not contain a dileucine-like motif flanking
the charged residues. Indeed, replacement of the KDDG
sequence in P-selectin by four alanines does not appar-
ently reduce targeting to LDCVs, and other signals in
P-selectin mediate localization to secretory vesicles (Blago-
veshchenskaya et al., 1999).
The signals that direct neurotransmitter transporters to
secretory vesicles presumably interact with a cytoplasmic
sorting machinery that may include clathrin adaptor pro-
teins, such as AP-1 and -2, and the related AP-3 and AP-4
(Bonifacino and Dell’Angelica, 1999). Dileucine motifs
are generally considered to interact directly with the b
subunit of adaptors (Rapoport et al., 1998). However,
acidic residues and phosphorylation sites upstream of dileu-
cine signals have also been implicated in the internaliza-
tion of plasma membrane proteins. These residues may
bind directly to the adaptors, or they may modulate adap-
tor binding indirectly (Dietrich et al., 1997). Regardless of
the precise mechanism, the spacing between these up-
stream residues and the leucines appears important and in
some cases, the upstream acidic residues and the two leu-
cines function as a single motif (Dietrich et al., 1997).
These observations suggest that the acidic residues up-
stream of the dileucine motif in VAChT and the VMATs
act in concert with the two leucines, or modulate their abil-
ity to interact with the cytoplasmic sorting machinery.
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the cell to affect localization to LDCVs. First, it could act
in the TGN to direct the vesicular transporters toward the
regulated secretory pathway (LDCVs) and away from the
constitutive secretory pathway. Second, it could influence
retrieval from immature LDCVs. Immature LDCVs con-
tain resident TGN proteins, such as furin (Dittie et al.,
1997), and lysosomal proteins, such as cathepsin B (Kulia-
wat et al., 1997). Maturation of the LDCVs involves the
removal of these proteins by an AP-1– and clathrin-depen-
dent mechanism (Dittie et al., 1996; Klumperman et al.,
1998), and phosphorylation of an acidic patch by casein ki-
nase II promotes retrieval by recruiting a novel cytosolic
protein (Wan et al., 1998). Acidic residues upstream of the
dileucine motifs present in the neurotransmitter transport-
ers might thus act by suppressing retrieval from immature
LDCVs, thereby increasing expression on mature LDCVs.
Third, the dileucine-based signals may influence the recy-
cling of VAChT and the VMATs from the cell surface af-
ter exocytosis. Upstream acidic residues may suppress lo-
cal recycling to endosomes or synaptic vesicles and so
direct the proteins to the TGN and then to LDCVs. The
precise membrane trafficking step(s) affected by acidic
residues upstream of the dileucine motif in vesicular trans-
porters remain to be determined. However, the role of the
dileucine motif in internalization from the plasma mem-
brane (Tan et al., 1998) indicates that the dileucine motif
itself functions at multiple trafficking steps, with the up-
stream acidic residues perhaps required for a subset of
these events.
Phosphorylation of Ser-480 in VAChT provides a nega-
tive charge similar to the glutamate present at this position
in the VMATs. Metabolic labeling in unstimulated PC12
cells indicates that constitutive phosphorylation may con-
tribute to the localization of wild-type VAChT. However,
since wild-type VAChT localizes to LDCVs in amounts
similar to the S480A mutant, constitutive phosphorylation
presumably occurs at low levels. Activation of PKC in-
creases VAChT phosphorylation, and may increase the lo-
calization of the transporter to LDCVs.
The localization of VAChT to LDCVs in PC12 cells has
relevance for the site of ACh storage in vivo. Although
SVs are generally considered to store and release from
ACh at the neuromuscular junction and in brain (Gilmor
et al., 1996; Weihe et al., 1996), ACh also appears in vesi-
cles similar to, or identical to LDCVs by biochemical frac-
tionation (Lundberg et al., 1981; Agoston and Whittaker,
1989). In addition, light microscopic analysis of brain sec-
tions shows a distribution for VAChT very similar to that
of VMAT2, with strong staining of cell bodies and den-
drites not observed with other synaptic vesicle proteins, in-
cluding the vesicular GABA transporter (Schafer et al.,
1995; Gilmor et al., 1996; Chaudhry et al., 1998). Thus, the
regulation of VAChT trafficking by phosphorylation of
Ser-480 may also influence the distribution of the protein
in vivo.
A change in the trafficking of VAChT has the potential
to affect transmitter release. A number of observations in-
dicate that vesicular transport activity influences the
amount of transmitter released per vesicle, or quantal size.
Mice heterozygous for a disruption of the VMAT2 gene
show dramatically reduced storage and release of dopa-
mine and serotonin (Fon et al., 1997). VMAT2 heterozy-
gotes (6) also show behavioral differences from wild-type
animals (Takahashi et al., 1997; Wang et al., 1997). In ad-
dition, overexpression of rat VAChT in Xenopus laevis
embryos generates larger postsynaptic quantal events in
cocultured myocytes (Song et al., 1997). Alterations in the
localization of VAChT to LDCVs (or SVs) may therefore
affect the amount of transmitter stored and released by
these vesicle populations.
The observations have relevance for certain forms of
neural plasticity. The neuromuscular junction exhibit con-
siderable variation in quantal size and the mechanism(s)
appears to be presynaptic (Van der Kloot, 1990; Williams,
1997). Drugs that inhibit vesicular ACh transport block
the regulation, implicating VAChT in the mechanism, and
protein phosphorylation also appears to be involved (Van
Der Kloot and Molgo, 1994). In the central nervous sys-
tem, PKC also modulates ACh release (Tanaka et al., 1986;
Allgaier et al., 1988). Activation of PKC increases VAChT
phosphorylation, as well as ACh release in hippocampal
synaptosomes, and the changes in transmitter release
require VAChT function (Barbosa et al., 1997). The phos-
phorylation of VAChT by PKC at Ser-480 may thus con-
tribute to multiple forms of neural plasticity by in-
fluencing the distribution of the transport protein on
neurosecretory vesicles. The difference that we have ob-
served between trafficking of S480A and S480E mutants
indicates the potential for phosphorylation at Ser-480 to
influence quantal size. The magnitude of the differences
in localization resembles the magnitude changes in quan-
tal size observed for other forms of synaptic plasticity
(Malenka and Nicoll, 1993). Further, the localization of
VAChT to LDCVs and its regulation by phosphorylation
of Ser-480 may specifically contribute to the giant end-
plate potentials observed at the neuromuscular junction
(Van der Kloot, 1990), and help to account for this poorly
understood mode of ACh release.
Figure 10. Immunoelectron microscopy of PC12 cells expressing wild-type and mutant VAChT. Immunogold-labeled cryosections
from PC12 cells expressing wild-type VAChT (A–C), S480A (D), or S480E (E) were examined by EM. Labeled LDCVs are indicated
by arrowheads, whereas VAChT-positive small vesicular profiles are indicated with an asterisk. A, VAChT (10-nm gold) is found in the
Golgi complex (G), as well as many neighboring vesicles (asterisk). LDCVs (arrowheads) are positive, but no label is found on lyso-
somes (L). B, Example of VAChT label (10-nm gold) in small vesicles close to an early endosomal vacuole (EE). C, Double immu-
nogold-labeling shows that synaptophysin (Sphy, 10-nm gold) colocalizes to a considerable extent with VAChT (15-nm gold) in small
vesicular profiles (asterisk). D, S480A (10-nm gold) localizes preferentially to small vesicles. E, By contrast, S480E (10-nm gold) is
found preferentially in LDCVs. The small arrow points to a clathrin-coated pit at the plasma membrane (P). LE, late endosome. Bars,
200 nm.The Journal of Cell Biology, Volume 149, 2000 394
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